Combining SBRT with DDR-targeted agents (e.g., ATM, DNA-PK, or PARP inhibitors) and immunomodulatory approaches holds promise for overcoming resistance and improving outcomes in prostate cancer. The gene discussed is ATM; the disease is prostate cancer.